Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on February 27, 2017. The filing discloses the entry into a material definitive agreement regarding the monetization of future royalty streams.
Key Financial Metrics and Transaction Details
The filing details a purchase and sale agreement between Perrigo Pharma International Designated Activity Company (a wholly owned subsidiary) and RPI Finance Trust, an affiliate of Royalty Pharma. The transaction involves the sale of rights to receive royalty payments from worldwide net sales of Tysabri® arising from January 1, 2017, onwards.
- Total Potential Purchase Price: Up to $2.85 billion.
- Closing Payment: $2.2 billion in cash.
- Contingent Payment 1: $250 million, payable if Tysabri® royalty thresholds are met for the twelve months ended December 31, 2018.
- Contingent Payment 2: $400 million, payable if Tysabri® royalty thresholds are met for the twelve months ended December 31, 2020.
- Guarantee: Perrigo has provided a limited guarantee of the subsidiary's obligations under the agreement.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period, as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Transaction Structure
The primary material change is the assignment of future royalty rights to a third party. The transaction is expected to close within 20 business days, subject to customary deliverables. The closing date may be extended by 10 business days at RPI's option upon the making of a $1 billion refundable purchase price deposit.
Outlook, Risks, and Contingencies
The transaction introduces contingent liabilities and future cash inflows dependent on the performance of Tysabri® sales. The agreement includes customary representations, warranties, covenants, and indemnification obligations. Perrigo retains certain information and audit rights related to the royalties.
Key Facts for Investor Verification
- Verify the specific royalty thresholds required to trigger the $250 million and $400 million contingent payments.
- Confirm the exact closing date and the status of the $1 billion deposit if the closing is extended.
- Review the full text of the Purchase and Sale Agreement (Exhibit 10.1) for detailed covenants and indemnification terms.
- Assess the impact of the $2.2 billion immediate cash inflow on the company's balance sheet and debt reduction strategy.